Talaris Therapeutics Inc.
12
0
0
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
58.3%
7 terminated/withdrawn out of 12 trials
12.5%
-74.0% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis
Role: lead
Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis
Role: lead
Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion
Role: lead
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
Role: lead
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation
Role: lead
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
Role: lead
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
Role: lead
Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)
Role: lead
Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)
Role: lead
Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion
Role: lead
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
Role: lead
Single Patient Expanded Access Protocol: Metabolic Boost
Role: lead
All 12 trials loaded